Novartis AG (NVSEF)
| Market Cap | 294.86B +16.4% |
| Revenue (ttm) | 57.36B +1.8% |
| Net Income | 10.03B -30.3% |
| EPS | 5.27 -28.3% |
| Shares Out | n/a |
| PE Ratio | 30.45 |
| Forward PE | 16.12 |
| Dividend | 4.75 (2.96%) |
| Ex-Dividend Date | Mar 10, 2026 |
| Volume | 914 |
| Open | 160.00 |
| Previous Close | 160.00 |
| Day's Range | 160.00 - 160.35 |
| 52-Week Range | 120.00 - 171.29 |
| Beta | 0.47 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 27, 2026 |
About Novartis AG
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure; Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6; Promacta/Revolade for immune thrombocytopenia (ITP), thrombocytopenia, and aplastic anemia ... [Read more]
Financial Performance
In 2025, Novartis AG's revenue was $56.67 billion, an increase of 9.57% compared to the previous year's $51.72 billion. Earnings were $13.98 billion, an increase of 17.11%.
Financial StatementsNews
Novartis price target raised to CHF 130 from CHF 120 at RBC Capital
RBC Capital raised the firm’s price target on Novartis (NVS) to CHF 130 from CHF 120 and keeps a Sector Perform rating on the shares. The company reported solid Q3…
Monte Rosa Therapeutics collaborator Novartis initiates MGD MRT-6160 study
Monte Rosa Therapeutics (GLUE) announced that its collaborator Novartis (NVS) has initiated a second Phase 2 clinical study for the VAV1-directed MGD MRT-6160 in people living with active moderate to…
Novartis price target raised to $163 from $156 at Morgan Stanley
Morgan Stanley analyst Thibault Boutherin raised the firm’s price target on Novartis (NVS) to $163 from $156 and keeps an Overweight rating on the shares. The firm sees upside to…
Novartis price target raised to CHF 130 from CHF 116 at UBS
UBS raised the firm’s price target on Novartis (NVS) to CHF 130 from CHF 116 and keeps a Neutral rating on the shares.
The Zacks Analyst Blog Highlights Eli Lilly, Novartis, Johnson & Johnson and AbbVie
Eli Lilly, Novartis, Johnson & Johnson and AbbVie advance arthritis treatment portfolios through strong drug sales, clinical progress and regulatory expansions.
What Novartis (NVS) Said on Its Q3 Earnings Call
Novartis NYSE: NVS reported third-quarter sales growth and margin expansion, supported by demand for priority medicines and productivity initiatives, while raising its full-year outlook for core opera...
Novartis Hikes Income Forecast, But There Were Caveats Within Its Report
Novartis stock rose slightly early Tuesday on strong third-quarter income, but the company's biggest moneymaker, Kisqali, fell short.
Novartis AG Earnings Call Transcript: Q3 2026
Q3 sales rose 4% and core operating income 10%, prompting higher FY2026 profit guidance. Growth drivers and launches offset generic pressure, while del-desiran and pelacarsen setbacks weighed on reported results and pipeline outlook.
Novartis AG Earnings release: Q3 2026
Novartis AG released its Q3 2026 earnings on October 27, 2026, summarizing the period's financial results.
Novartis AG Slides: Q3 2026
Novartis AG has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on October 27, 2026.
Novartis AG Quarterly report: Q3 2026
Novartis AG has published its Q3 2026 quarterly earnings report on October 27, 2026.
The Zacks Analyst Blog Highlights Intel, Novartis AG, Itau Unibanco and AMREP
Intel, Novartis, Itau Unibanco and AMREP face distinct growth opportunities and risks, from AI expansion and drug sales to banking growth and real estate development.
Novartis AG Reports Q3 2026 Financial Results and Raises Full-Year Core Operating Income Guidance
Novartis AG reported net sales of USD 14.5 billion for the third quarter of 2026, representing a 4% increase in constant currencies and USD compared to the prior year. Operating income declined 59% to...
Novartis reports Q3 core EPS $2.46 vs. $2.25 last year
Reports Q3 net sales $14.5B vs. $13.9B last year. Commenting on Q3 2026 results, Vas Narasimhan, CEO of Novartis (NVS), said: “Novartis delivered solid sales growth in Q3, as priority…
Novartis CEO says company must stay 'courageous' to pursue breakthroughs
Novartis CEO Vas Narasimhan tells CNBC the company must keep pursuing acquisitions that could deliver breakthroughs for patients.
Novartis CEO says AI has tangibly improved P&L for the first time
Novartis CEO, Vas Narasimhan, discusses how AI is beginning to impact the company’s operations. Narasimhan was speaking to CNBC's Carolin Roth around the company's third quarter earnings, a day after ...
Novartis Q3 Profit Sinks 70% Despite Sales Growth; Lifts FY26 Core Income View, Backs Sales Outlook
(RTTNews) - Novartis AG (NVS) reported Tuesday a sharp decline in third-quarter profit, reflecting an impairment charge and higher interest expense, despite increased sales.
Novartis Raises Guidance Despite Trial Setbacks Hitting Profit
The Swiss drugmaker cited solid sales growth and productivity gains, even as recent clinical-trial setbacks hit its bottom line in the third quarter.
Novartis Q3 Profit Declines; Lifts FY26 Core Income View, Backs Sales Outlook
(RTTNews) - Swiss drug major Novartis AG (NVS, NOVN.SW) reported Tuesday sharply lower profit in its third quarter, mainly hurt by an impairment charge and higher expenses, despite growth in net sales...
Novartis raises full year core operating income guidance
Novartis raised its full-year core operating income guidance on Tuesday after strong third-quarter demand for its key cancer and multiple sclerosis drugs.
Top Analyst Reports for Intel, Novartis & Itau Unibanco
Intel's manufacturing recovery and AI expansion, Novartis' growth drugs and Itau Unibanco's strategic moves headline today's top analyst reports.
Novartis Remibrutinib Cuts MS Relapses in Phase III, Eyes $4B Opportunity
Novartis NYSE: NVS presented Phase III results for remibrutinib in relapsing multiple sclerosis, reporting that the oral Bruton's tyrosine kinase inhibitor reduced relapse rates and MRI lesion activit...
Novartis AG Transcript: Investor update
REMODEL-1 and -2 showed lower relapse and MRI activity, with a significant 6-month disability-progression benefit and a favorable reported safety profile. Management sees $4bn-plus RMS potential, with further SPMS upside and broader pipeline opportunities.
Novartis AG Slides: Investor update
Novartis AG has posted slides in relation to its latest quarterly earnings report, which was published on October 23, 2026.
Novartis presents weaker-than-expected relapse data for multiple sclerosis drug remibrutinib
Swiss drugmaker Novartis' oral multiple sclerosis (MS) drug remibrutinib meaningfully reduced relapses in patients, according to data presented at a medical conference in Toronto on Friday, but less ...